Chapter/Section Purchase

1 Study Coverage
1.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022) & (US$ Million) Introduction
1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Outlook 2017 VS 2022 VS 2028
1.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size for the Year 2017-2028
1.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size for the Year 2017-2028
1.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.3.1 The Market Share of United States Paroxysmal Nocturnal Hemoglobinuria Treatment in Global, 2017 VS 2022 VS 2028
1.3.2 The Growth Rate of Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size, United States VS Global, 2017 VS 2022 VS 2028
1.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Dynamics
1.4.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Industry Trends
1.4.2 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Drivers
1.4.3 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Challenges
1.4.4 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Restraints
1.5 Study Objectives
1.6 Years Considered
2 Paroxysmal Nocturnal Hemoglobinuria Treatment by Type
2.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Segment by Type
2.1.1 ACH-4471
2.1.2 ALN-CC5
2.1.3 ALXN-1210
2.1.4 AMY-101
2.1.5 APL-2
2.1.6 Others
2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2017, 2022 & 2028)
2.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2017-2028)
2.4 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2017, 2022 & 2028)
2.5 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Type (2017-2028)
3 Paroxysmal Nocturnal Hemoglobinuria Treatment by Application
3.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Segment by Application
3.1.1 Hospital
3.1.2 Clinic
3.1.3 Others
3.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2017, 2022 & 2028)
3.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2017-2028)
3.4 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2017, 2022 & 2028)
3.5 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Application (2017-2028)
4 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Competitor Landscape by Company
4.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Company
4.1.1 Top Global Paroxysmal Nocturnal Hemoglobinuria Treatment Companies Ranked by Revenue (2021)
4.1.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Player (2017-2022)
4.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Concentration Ratio (CR)
4.2.1 Paroxysmal Nocturnal Hemoglobinuria Treatment Market Concentration Ratio (CR) (2017-2022)
4.2.2 Global Top 5 and Top 10 Largest Companies of Paroxysmal Nocturnal Hemoglobinuria Treatment in 2021
4.2.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
4.3 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Headquarters, Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022) & (US$ Million) Type
4.3.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Headquarters and Area Served
4.3.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Companies Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022) & (US$ Million) Type
4.3.3 Date of International Companies Enter into Paroxysmal Nocturnal Hemoglobinuria Treatment Market
4.4 Companies Mergers & Acquisitions, Expansion Plans
4.5 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Company
4.5.1 Top Paroxysmal Nocturnal Hemoglobinuria Treatment Players in United States, Ranked by Revenue (2021)
4.5.2 United States Paroxysmal Nocturnal Hemoglobinuria Treatment Revenue by Players (2020, 2021 & 2022)
5 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region
5.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region: 2017 VS 2022 VS 2028
5.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2017-2028)
5.2.1 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region: 2017-2022
5.2.2 Global Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size by Region (2023-2028)
6 Segment in Region Level & Country Level
6.1 North America
6.1.1 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth 2017-2028
6.1.2 North America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.1.3 U.S.
6.1.4 Canada
6.2 Asia-Pacific
6.2.1 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth 2017-2028
6.2.2 Asia-Pacific Paroxysmal Nocturnal Hemoglobinuria Treatment Market Facts & Figures by Region (2017, 2022 & 2028)
6.2.3 China
6.2.4 Japan
6.2.5 South Korea
6.2.6 India
6.2.7 Australia
6.2.8 Taiwan
6.2.9 Indonesia
6.2.10 Thailand
6.2.11 Malaysia
6.2.12 Philippines
6.3 Europe
6.3.1 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth 2017-2028
6.3.2 Europe Paroxysmal Nocturnal Hemoglobinuria Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.3.3 Germany
6.3.4 France
6.3.5 U.K.
6.3.6 Italy
6.3.7 Russia
6.4 Latin America
6.4.1 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth 2017-2028
6.4.2 Latin America Paroxysmal Nocturnal Hemoglobinuria Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.4.3 Mexico
6.4.4 Brazil
6.4.5 Argentina
6.5 Middle East and Africa
6.5.1 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Size YoY Growth 2017-2028
6.5.2 Middle East and Africa Paroxysmal Nocturnal Hemoglobinuria Treatment Market Facts & Figures by Country (2017, 2022 & 2028)
6.5.3 Turkey
6.5.4 Saudi Arabia
6.5.5 U.A.E
7 Company Profiles
7.1 Achillion Pharmaceuticals Inc
7.1.1 Achillion Pharmaceuticals Inc Company Details
7.1.2 Achillion Pharmaceuticals Inc Business Overview
7.1.3 Achillion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.1.4 Achillion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.1.5 Achillion Pharmaceuticals Inc Recent Development
7.2 Akari Therapeutics Plc
7.2.1 Akari Therapeutics Plc Company Details
7.2.2 Akari Therapeutics Plc Business Overview
7.2.3 Akari Therapeutics Plc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.2.4 Akari Therapeutics Plc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.2.5 Akari Therapeutics Plc Recent Development
7.3 Alexion Pharmaceuticals Inc
7.3.1 Alexion Pharmaceuticals Inc Company Details
7.3.2 Alexion Pharmaceuticals Inc Business Overview
7.3.3 Alexion Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.3.4 Alexion Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.3.5 Alexion Pharmaceuticals Inc Recent Development
7.4 Alnylam Pharmaceuticals Inc
7.4.1 Alnylam Pharmaceuticals Inc Company Details
7.4.2 Alnylam Pharmaceuticals Inc Business Overview
7.4.3 Alnylam Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.4.4 Alnylam Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.4.5 Alnylam Pharmaceuticals Inc Recent Development
7.5 Amgen Inc
7.5.1 Amgen Inc Company Details
7.5.2 Amgen Inc Business Overview
7.5.3 Amgen Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.5.4 Amgen Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.5.5 Amgen Inc Recent Development
7.6 Apellis Pharmaceuticals Inc
7.6.1 Apellis Pharmaceuticals Inc Company Details
7.6.2 Apellis Pharmaceuticals Inc Business Overview
7.6.3 Apellis Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.6.4 Apellis Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.6.5 Apellis Pharmaceuticals Inc Recent Development
7.7 F. Hoffmann-La Roche Ltd
7.7.1 F. Hoffmann-La Roche Ltd Company Details
7.7.2 F. Hoffmann-La Roche Ltd Business Overview
7.7.3 F. Hoffmann-La Roche Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.7.4 F. Hoffmann-La Roche Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.7.5 F. Hoffmann-La Roche Ltd Recent Development
7.8 ISU ABXIS Co Ltd
7.8.1 ISU ABXIS Co Ltd Company Details
7.8.2 ISU ABXIS Co Ltd Business Overview
7.8.3 ISU ABXIS Co Ltd Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.8.4 ISU ABXIS Co Ltd Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.8.5 ISU ABXIS Co Ltd Recent Development
7.9 Novartis AG
7.9.1 Novartis AG Company Details
7.9.2 Novartis AG Business Overview
7.9.3 Novartis AG Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.9.4 Novartis AG Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.9.5 Novartis AG Recent Development
7.10 NovelMed Therapeutics Inc
7.10.1 NovelMed Therapeutics Inc Company Details
7.10.2 NovelMed Therapeutics Inc Business Overview
7.10.3 NovelMed Therapeutics Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.10.4 NovelMed Therapeutics Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.10.5 NovelMed Therapeutics Inc Recent Development
7.11 Omeros Corp
7.11.1 Omeros Corp Company Details
7.11.2 Omeros Corp Business Overview
7.11.3 Omeros Corp Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.11.4 Omeros Corp Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.11.5 Omeros Corp Recent Development
7.12 Ra Pharmaceuticals Inc
7.12.1 Ra Pharmaceuticals Inc Company Details
7.12.2 Ra Pharmaceuticals Inc Business Overview
7.12.3 Ra Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.12.4 Ra Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.12.5 Ra Pharmaceuticals Inc Recent Development
7.13 Regeneron Pharmaceuticals Inc
7.13.1 Regeneron Pharmaceuticals Inc Company Details
7.13.2 Regeneron Pharmaceuticals Inc Business Overview
7.13.3 Regeneron Pharmaceuticals Inc Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.13.4 Regeneron Pharmaceuticals Inc Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.13.5 Regeneron Pharmaceuticals Inc Recent Development
7.14 Regenesance BV
7.14.1 Regenesance BV Company Details
7.14.2 Regenesance BV Business Overview
7.14.3 Regenesance BV Paroxysmal Nocturnal Hemoglobinuria Treatment Introduction
7.14.4 Regenesance BV Revenue in Paroxysmal Nocturnal Hemoglobinuria Treatment Business (2017-2022)
7.14.5 Regenesance BV Recent Development
8 Research Findings and Conclusion
9 Appendix
9.1 Research Methodology
9.1.1 Methodology/Research Approach
9.1.2 Data Source
9.2 Author Details
9.3 Disclaimer